Rodon J et al. |
Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study. |
2008 |
Cancer Chemother. Pharmacol. |
pmid:18301896
|
Galsky MD et al. |
Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer. |
2008 |
J. Clin. Oncol. |
pmid:18362364
|
Taft F et al. |
Highly active ansamitocin derivatives: mutasynthesis using an AHBA-blocked mutant. |
2008 |
Chembiochem |
pmid:18381586
|
Ostermann E et al. |
Effective immunoconjugate therapy in cancer models targeting a serine protease of tumor fibroblasts. |
2008 |
Clin. Cancer Res. |
pmid:18628473
|
Stephan JP et al. |
Anti-CD22-MCC-DM1 and MC-MMAF conjugates: impact of assay format on pharmacokinetic parameters determination. |
2008 |
Bioconjug. Chem. |
pmid:18637680
|
Zhao P et al. |
Amide N-glycosylation by Asm25, an N-glycosyltransferase of ansamitocins. |
2008 |
Chem. Biol. |
pmid:18721757
|
Bai RL et al. |
Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data. |
1991 |
J. Biol. Chem. |
pmid:1874739
|
Hull RN et al. |
Studies on tissue culture produced plasminogen activator. I. Preliminary observations and the enhancing effect of colchicine and other antimitotic agents. |
1977 |
Thromb. Res. |
pmid:18812
|
Arai MA et al. |
Hedgehog/GLI-mediated transcriptional inhibitors from Zizyphus cambodiana. |
2008 |
Bioorg. Med. Chem. |
pmid:18842418
|
Lewis Phillips GD et al. |
Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. |
2008 |
Cancer Res. |
pmid:19010901
|
Polson AG et al. |
Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection. |
2009 |
Cancer Res. |
pmid:19258515
|
Taft F et al. |
Timing of the Delta(10,12)-Delta(11,13) double bond migration during ansamitocin biosynthesis in Actinosynnema pretiosum. |
2009 |
J. Am. Chem. Soc. |
pmid:19292483
|
Wang L et al. |
Formal total synthesis of N-methylmaysenine. |
2009 |
Org. Lett. |
pmid:19296671
|
Ikeda H et al. |
The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. |
2009 |
Clin. Cancer Res. |
pmid:19509164
|
Al-Katib AM et al. |
Superior antitumor activity of SAR3419 to rituximab in xenograft models for non-Hodgkin's lymphoma. |
2009 |
Clin. Cancer Res. |
pmid:19509168
|
Tang R et al. |
P-gp activity is a critical resistance factor against AVE9633 and DM4 cytotoxicity in leukaemia cell lines, but not a major mechanism of chemoresistance in cells from acute myeloid leukaemia patients. |
2009 |
BMC Cancer |
pmid:19549303
|
Ng D et al. |
Constitutive overexpression of asm2 and asm39 increases AP-3 production in the actinomycete Actinosynnema pretiosum. |
2009 |
J. Ind. Microbiol. Biotechnol. |
pmid:19609582
|
Zheng B et al. |
In vivo effects of targeting CD79b with antibodies and antibody-drug conjugates. |
2009 |
Mol. Cancer Ther. |
pmid:19808977
|
Erickson HK et al. |
Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates. |
2010 |
Bioconjug. Chem. |
pmid:19891424
|
Haeuw JF et al. |
[Immunoconjugates, drug-armed antibodies to fight against cancer]. |
2009 |
Med Sci (Paris) |
pmid:20035677
|